论文部分内容阅读
按临床表现、体征、ＦＴ３、ＦＴ４、ＴＳＨ测定及治疗情况将６３例Ｇｒａｖｅｓ病患者分为未治组与治疗缓解组。用ＥＬＩＳＡ法测定血清ＳＩＬ－２Ｒ。结果显示血清ＳＩＬ－２Ｒ未治组与治疗缓解组相比是显著增高的（Ｐ＜０．０１），但治疗缓解组与正常对照组无差异。血清ＳＩＬ－２Ｒ在未治组与ＦＴ３水平及甲状腺刺激抗体（ＴＳＩ）、甲状腺蛋白抗体（ＴＧ－Ａｂ）滴度呈正相关（ｒ分别为０．６７８、０．５８０、０．７３０，Ｐ均＜０．０１）。提示：血清ＳＩＬ－２Ｒ水平可作为判断Ｇｒａｖｅｓ病活动及治疗效果的一种有价值的免疫学指标
According to the clinical manifestations, signs, FT3, FT4, TSH determination and treatment of 63 patients with Graves disease were divided into untreated and treatment-response groups. Serum SIL-2R was measured by ELISA. The results showed that serum SIL-2R in untreated group was significantly higher than that in treatment-remission group (P <0.01), but there was no difference between treatment-remission group and normal control group. Serum SIL-2R levels were positively correlated with FT3 levels and thyroid stimulating antibody (TSI) and thyroid protein antibody (TG-Ab) titers in the untreated group (r = 0.678,0.580,0.730, P < 0.01). Tip: The level of serum SIL-2R can be used as a valuable immunological indicator to judge Graves disease activity and therapeutic effect